254 related articles for article (PubMed ID: 31132435)
1. New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease.
Zueva I; Dias J; Lushchekina S; Semenov V; Mukhamedyarov M; Pashirova T; Babaev V; Nachon F; Petrova N; Nurullin L; Zakharova L; Ilyin V; Masson P; Petrov K
Neuropharmacology; 2019 Sep; 155():131-141. PubMed ID: 31132435
[TBL] [Abstract][Full Text] [Related]
2. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
Zueva IV; Semenov VE; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS
Int J Risk Saf Med; 2015; 27 Suppl 1():S69-71. PubMed ID: 26639718
[TBL] [Abstract][Full Text] [Related]
3. 6-Methyluracil Derivatives as Bifunctional Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease.
Semenov VE; Zueva IV; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS
ChemMedChem; 2015 Nov; 10(11):1863-74. PubMed ID: 26412714
[TBL] [Abstract][Full Text] [Related]
4. Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: mechanism and possible advantages for myasthenia gravis treatment.
Kharlamova AD; Lushchekina SV; Petrov KA; Kots ED; Nachon F; Villard-Wandhammer M; Zueva IV; Krejci E; Reznik VS; Zobov VV; Nikolsky EE; Masson P
Biochem J; 2016 May; 473(9):1225-36. PubMed ID: 26929400
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a New Donepezil-like Acetylcholinesterase Inhibitor for Targeting Alzheimer's Disease: Computational Studies with Biological Validation.
Akhoon BA; Choudhary S; Tiwari H; Kumar A; Barik MR; Rathor L; Pandey R; Nargotra A
J Chem Inf Model; 2020 Oct; 60(10):4717-4729. PubMed ID: 32955256
[TBL] [Abstract][Full Text] [Related]
7. Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Wang ZM; Cai P; Liu QH; Xu DQ; Yang XL; Wu JJ; Kong LY; Wang XB
Eur J Med Chem; 2016 Nov; 123():282-297. PubMed ID: 27484514
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine.
Jiang X; Liu C; Zou M; Xie H; Lin T; Lyu W; Xu J; Li Y; Feng F; Sun H; Liu W
Eur J Med Chem; 2021 Nov; 223():113663. PubMed ID: 34198150
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
Son M; Park C; Rampogu S; Zeb A; Lee KW
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823604
[TBL] [Abstract][Full Text] [Related]
10. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Castro A; Martinez A
Mini Rev Med Chem; 2001 Sep; 1(3):267-72. PubMed ID: 12369973
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors.
Gabr MT; Abdel-Raziq MS
Bioorg Chem; 2018 Oct; 80():245-252. PubMed ID: 29966870
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T; Hosseini SM; Nordberg A
J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
[TBL] [Abstract][Full Text] [Related]
13. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease.
Dong H; Csernansky CA; Martin MV; Bertchume A; Vallera D; Csernansky JG
Psychopharmacology (Berl); 2005 Aug; 181(1):145-52. PubMed ID: 15778881
[TBL] [Abstract][Full Text] [Related]
14. Donepezil-Inspired Multitargeting Indanone Derivatives as Effective Anti-Alzheimer's Agents.
Singh JV; Thakur S; Kumar N; Singh H; Mithu VS; Singh H; Bhagat K; Gulati HK; Sharma A; Singh H; Sharma S; Bedi PMS
ACS Chem Neurosci; 2022 Mar; 13(6):733-750. PubMed ID: 35195392
[TBL] [Abstract][Full Text] [Related]
15. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.
Kryger G; Silman I; Sussman JL
Structure; 1999 Mar; 7(3):297-307. PubMed ID: 10368299
[TBL] [Abstract][Full Text] [Related]
16. Donepezil attenuates Aβ-associated mitochondrial dysfunction and reduces mitochondrial Aβ accumulation in vivo and in vitro.
Ye CY; Lei Y; Tang XC; Zhang HY
Neuropharmacology; 2015 Aug; 95():29-36. PubMed ID: 25744714
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
Lan JS; Zhang T; Liu Y; Yang J; Xie SS; Liu J; Miao ZY; Ding Y
Eur J Med Chem; 2017 Jun; 133():184-196. PubMed ID: 28388521
[TBL] [Abstract][Full Text] [Related]
18. Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
Sharma P; Tripathi MK; Shrivastava SK
Methods Mol Biol; 2020; 2089():257-286. PubMed ID: 31773661
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of donepezil administration on acetylcholinesterase activity and altered redox homeostasis in Alzheimer's disease.
Atukeren P; Cengiz M; Yavuzer H; Gelisgen R; Altunoglu E; Oner S; Erdenen F; Yuceakın D; Derici H; Cakatay U; Uzun H
Biomed Pharmacother; 2017 Jun; 90():786-795. PubMed ID: 28427041
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
Nagakura A; Shitaka Y; Yarimizu J; Matsuoka N
Eur J Pharmacol; 2013 Mar; 703(1-3):53-61. PubMed ID: 23276665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
